Rubix LS

How much do we really know about MS, and what breakthroughs are shaping the future of treatment? Let’s dive in. The Current Landscape of MS 🔹 Who’s Affected? MS impacts approximately 2.9 million people worldwide, including nearly 1 million in the U.S. alone. 🔹 What’s New in Research? Scientists discovered that neurons in MS lesions accumulate mutations at a rate 2.5 times higher than those in non-MS brains. Are There Promising Treatments? 💊 ADS-5102 is currently in clinical trials, aiming to improve walking impairments in MS patients. 💊 Sanofi’s tolebrutinib has shown a 31% reduction in progressive MS—a huge leap forward. Why Awareness Matters MS doesn’t just affect individuals—it reshapes lives, workplaces, and communities. So, how can we help? ✔️ Raise Awareness – Education leads to earlier diagnosis and better support. ✔️ Fund Research – Every breakthrough starts with funding. ✔️ Create Inclusive Spaces – Accessible workplaces and supportive policies matter. This MS Awareness Month, let’s turn knowledge into action. How will you contribute? #MultipleSclerosis #BreakthroughMedicine

Nine years ago, Rubix LS set out to reshape clinical research—focusing on expanding access, improving outcomes, and ensuring breakthroughs reach the patients who need them most. Today, that mission is stronger than ever. Over the years, we've: ✅ Conducted WHO-backed trials impacting women’s health and infectious disease ✅ Partnered with industry leaders to accelerate clinical innovation ✅ Built a powerful data ecosystem—now at 18M+ datasets—to support trials with multiple partners and drive better decision-making This milestone isn’t just about the past—it’s about the future. With data, expertise, and the right collaborators, we’re committed to making clinical research smarter, faster, and more inclusive. Check out our latest report to see how far we’ve come and where we’re headed next: https://lnkd.in/evnT4Hcm

Should diversity in clinical trials be a regulatory checkbox or a competitive advantage? Many treatments fail to serve the full patient population because clinical trials lack diversity. Yet, pharma executives who prioritize clinicoequity aren’t just improving patient outcomes, they’re making smarter business moves. Clinicoequity isn’t just a trend. It’s backed by research. Studies show that diverse clinical trials lead to more effective treatments, stronger regulatory approvals, and greater trust in medicine. Relevant studies: 🔎Bridging the Gap in AI Integration: Enhancing Clinician Education and Establishing Pharmaceutical-Level Regulation for Ethical Healthcare 🔎Trends and Landscape of Clinical Outcome Assessment Use to Support Oncology Product Approvals The Bottom Line? Clinicoequity isn’t just ethical. It’s strategic. Companies leading in inclusivity are winning in innovation, trust, and regulatory success. What’s your take? Should pharma see clinicoequity as a moral duty, a business strategy or both? Let’s discuss! ⬇️ #ClinicalTrials #DiversityInResearch #HealthEquity #Clinicoequity #RubixLS

Exciting News: Rubix LS is heading to San Diego for the US Clinical Trials Innovation Programme 2025! 📍Mark your calendars for March 3-4 at the Hilton San Diego Bayfront—where the brightest minds in clinical research will gather to push innovation forward. From accelerating trial diversity to leveraging real-world data, this event is set to spark critical conversations that shape the future of clinical development. And we can’t wait to be part of it! Who else is attending? Let’s connect and make the most of this opportunity. Shoutout to World BI and Clinical Trials Conclave (CTC) for bringing the industry together for such a crucial discussion! #ClinicalTrials #Innovation #USCTIP2025

On February 13th, our CEO, Reginald Swift, joined an incredible panel at LabCentral, diving into one of the biggest challenges in healthcare: putting patients at the center of rare disease research—and making sure AI is a force for good. ⚖️From powerful patient stories to real strategies for health equity, the discussion was raw, insightful, and necessary. Huge thanks to Sheila Phicil, MPH, MS, PMP, FACHE, Fiona Mack, Cameron Trenor, MD, Dorosella Green, MS-PREP, and everyone who showed up ready to push for real change. Let’s keep this momentum going! Chaeli Wallace Natalie Man #HealthEquity #AIinHealthcare #RareDisease

Clinical research isn’t one-size-fits-all. Yet, too often, clinical trials still fall short in representing the real-world diversity of patients. Traditional diversity efforts focus on recruitment, but true equity requires rethinking trial design itself. 🔹 How do race, gender, income, and geography intersect to impact health outcomes? 🔹 What systemic barriers prevent meaningful participation in trials? 🔹 How can the industry move beyond surface-level diversity to real clinicoequity? Our latest piece explores why intersectionality is the missing key in clinical research—and how leaders in pharma can take action. Read more here: 👇🏽 https://lnkd.in/g6KZmjWF #ClinicalResearch #DiversityInTrials #HealthEquity

“From HeLa to Health Equity: A Tribute to Diverse Contributions” was held at LabCentral tonight recognizing the endless but unconsented contributions of Henrietta Lacks immortalized HeLa cell lines - the panel of speakers ranging from patients to pharma to clinicians underlined the power, value, and critical importance of health equity in our society - without that we all suffer. Thank you to everyone involved in tonight’s event - the stories and questions and inspiration stays with me. Sheila Phicil, MPH, MS, PMP, FACHE Chaeli Wallace Natalie Man, Fiona Mack Bayer Co.Lab Bayer Rubix LS Reginald Swift Dorosella Green, MS-PREP TAKEDA PHARMACEUTICALS AMERICA, INC. Cameron Trenor, MD Cellarity Shazia Mir Jonathan Sanchez Kristin Cabrera Spencer Plourde Rachele Ryan

Duchenne Muscular Dystrophy (DMD) is a rare but severe genetic disorder that leads to progressive muscle weakness and loss. It primarily affects boys, with symptoms appearing as early as age 2-3. Over time, it impacts mobility, heart, and lung function—yet we still have major gaps in research. Why this matters: 🔹 Affects ~1 in 3,500 - 6,000 boys worldwide. 🌍 🔹 No cure yet—but advances in gene therapy & clinical trials offer hope! 🔹 Limited data, especially in underserved communities. 🔹 Clinical trials are scarce—Only 65 trials are currently recruiting, and research funding remains a challenge. What can we do? ✔️ Raise awareness through social media, events, and conversations. ✔️ Support clinical trials—Only 65 trials are currently recruiting, we definitely need more. ✔️ Push for inclusion in research. ✔️ Fundraise for research & patient support. ✔️ Promote newborn screening and genetic testing. ✔️ Engage policymakers to improve access to treatments and research funding. We can’t afford to leave anyone behind in the fight against DMD. More research, more trials, and more inclusivity will bring us closer to real solutions. 💪 #DuchenneAwareness #ClinicalResearch #HopeForACure

Have you heard? A single cell changed the world. And now, we’re asking - how can we change it for the better? 📅 Date: February 13th, 2025 ⏰ Time: 4:30 PM 📍 Location: LabCentral, 700 Main St, Cambridge, MA Back in 1951, Henrietta Lacks’ cells (HeLa) were taken without her consent, yet they powered some of the biggest medical breakthroughs - vaccines, cancer treatments and, even gene mapping! But her story also highlights something we still need to fix: #HealthEquity. So, how do we put patients at the center of rare disease research? And how can AI help (not hurt) the fight for fair access to care? Let’s talk about it. Join us at LabCentral where top experts will share how we can combat these challenges and drive real change: 💡 Amplifying patient voices in innovation 💡 Breaking down barriers to equitable access 💡 Harnessing AI to transform rare disease care Meet the panelists: 🤝 Reginald Swift (Rubix LS) – Championing patient-centered tech 🤝 Fiona Mack (Bayer Co.Lab) – Accelerating biotech innovation 🤝 Dorosella Green, MS-PREP (Takeda) – Embedding health equity in patient care 🤝 Cameron Trenor, MD (Cellarity) – Using AI to revolutionize sickle cell treatment Hosted by Sheila Phicil, MPH, MS, PMP, FACHE Don’t just read about change, be part of it. See you there! #RareDisease #ArtificialIntelligence #Healthcare #PatientCenteredCare

💡 Forget what you thought you knew about drug development. AI is rewriting the rules, and the possibilities are limitless. This video explores the convergence of AI, quantum computing, and synthetic biology, showcasing how these powerful forces are unlocking unprecedented breakthroughs in the fight against disease. The future of health is being written now. 👇🏼 #DrugDevelopment #ArtificialIntelligence #Innovation